Skip to main content

Medication & Treatment

People with diabetes use many medications to both manage blood sugar levels and also to prevent or treat health complications.

For people with type 1 diabetes, the most important drug is insulin; some people with type 2 diabetes also take insulin. For people with type 2 diabetes, glucose-lowering medications include metformin, sulfonylureas, TZDs, SGLT-2 inhibitors, GLP-1 agonists, DPP-4 inhibitors, and more.

Some of these drugs are injected, others are taken in pill form, and some are even inhaled. Learn about the different treatment options available and which might be best for your lifestyle.

Metformin
Insulin
SGLT-2 inhibitors
GLP-1 agonists
DPP-4 inhibitors
Combination drugs
Sulfonylureas (SFUs)
TZDs

What's new

Results from recent clinical trials have shown that GLP-1 receptor agonist medications are effective at lowering A1C and body weight.  Continue Reading »

diaTribe is excited to bring you additional expanded coverage from the EASD 2021 virtual conference this past week! Find out more from leading clinicians and researchers around the world on insights into the latest data on automated insulin delivery, diet and nutrition, SGLT-2s, GLP-1s, and chronic kidney disease. Continue Reading »

Weight management is no easy task, but achieving and maintaining a healthy weight is important for your well-being, your diabetes management, and your overall health. Continue Reading »

The FDA and the FTC sent warning letters to 10 companies falsely claiming to sell dietary supplements that could cure, treat, mitigate, or prevent diabetes. People are strongly encouraged to avoid these products until they have undergone the proper testing. Continue Reading »

Kerendia (also known as finerenone) can reduce the risk of heart attacks, hospitalization for heart failure, and cardiovascular death for adults with chronic kidney disease in people with type 2 diabetes. Continue Reading »

​This international clinical trial is enrolling an estimated 1,224 participants who have been diagnosed with type 2 diabetes, age 18 or older. This study is investigating if higher doses of oral semaglutide (currently sold as Rybelsus) will lead to lower A1C levels.  Continue Reading »

Jardiance (empagliflozin), an SGLT-2 inhibitor, was approved by the FDA to help adults who have heart failure with reduced ejection fraction (HFrEF). Results from EMPEROR-Preserved also show Jardiance benefits those with heart failure with preserved ejection fraction (HFpEF). The FDA has now approved Jardiance for all people with heart failure regardless of diabetes status. Continue Reading »

In this clinical trial, researchers are studying the effectiveness of dapagliflozin and saxagliptin in children and adolescents with type 2 diabetes. While these drugs are different, one is an SGLT-2 inhibitor and one is a DPP-4 inhibitor, and both have shown to lower blood glucose in adults with type 2 diabetes. Learn more about how to get involved. Continue Reading »

Pages